Universal immunization with nirsevimab reduces hospital admissions for respiratory syncytial virus (RSV) bronchiolitis by over 80 percent in infants under six months of age, according to a clinical study published in The Pediatric Infectious Disease Journal and reported by EFE.
Clinical Efficacy and Epidemiological Impact in Infants
Respiratory syncytial virus remains a primary driver of lower respiratory tract infections in early childhood. Data from a longitudinal analysis conducted at Hospital Joan XXIII in Tarragona, in collaboration with the Universitat Rovira i Virgili (URV), evaluated 1,384 hospitalizations across six epidemic seasons spanning 2018 to 2025. The findings demonstrate that nirsevimab administration cuts infant hospital admissions by more than 80 percent in the most vulnerable age bracket.
Beyond general ward admissions, the intervention yields a significant decline in severe disease trajectories. Pediatric Intensive Care Unit (PICU) admissions for RSV dropped by more than 55 percent among infants under six months. Meanwhile, pediatric ICU admissions for lower respiratory infections declined from 2.9 to 1.3 cases per 1,000 children.
Esther Parada, a pediatrician at Hospital Joan XXIII and lead investigator of the study, emphasized the clinical value of the drug for young infants. The results confirm that the nirsevimab is being very effective in the children under six months, which is precisely the group of age most vulnerable and the one that presents more severe forms of the disease,
Parada noted.
In Plain English: The Clinical Takeaway
- Targeted Protection: Nirsevimab is given to infants to prevent severe RSV disease during their first winter season.
- Measurable Safety: Clinical data show an 80 percent drop in hospital admissions without triggering a surge in other respiratory infections or worsening illness in subsequent years.
- Duration of Defense: The immunization protects babies during their peak window of vulnerability without negative rebound effects later in childhood.
Addressing Viral Replacement and Longitudinal Safety Concerns
Clinicians questioned whether suppressing RSV would clear a biological pathway for other respiratory pathogens to cause equal or greater harm, or if uninfected infants would simply experience severe RSV disease during their second year of life.
The research team tracked these outcomes closely across multiple seasons. Analysts detected no compensatory rise in hospital admissions driven by alternative respiratory viruses. In fact, investigators observed a reduction in overall non-RSV lower respiratory admissions. Furthermore, children who received nirsevimab during their first season did not display elevated disease severity or higher hospitalization rates when exposed to the virus the following year.
What we observe is that the immunization protects the babies in the moment in which they are more vulnerable, without this behaving negative consequences in subsequent seasons,
Parada explained regarding the long-term safety profile.
| Clinical Metric | Baseline Rate (per 1,000 children < 5 years) | Post-Intervention Rate (per 1,000 children < 5 years) |
|---|---|---|
| RSV Hospitalization Rate | 5.04 cases | 2.51 cases |
| Pediatric ICU Respiratory Admissions | 2.9 cases | 1.3 cases |
| Infant (<6 months) RSV Admissions | Reduced by >80% | — |
| Infant (<6 months) PICU Admissions | Reduced by >55% | — |
Disclaimer: This article is for informational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified pediatrician or healthcare provider with any questions regarding a medical condition or immunization schedule.
